















Dana-Farber Cancer Institute











Association of **American Cancer Institutes**



























American Lung Association.







Seattle Indian Health Board

For the Love of Native People



















National Kidney Foundation[®]





















Tomorrow can't wait

cancer

alliance































BE















THE MATCH

















May 11, 2022

The Honorable Patty Murray Chairwoman Committee on Health, Education, Labor & Pensions United States Senate Washington, D.C. 20510

The Honorable Richard Burr Ranking Member Committee on Health, Education, Labor & Pensions United States Senate Washington, D.C. 20510 The Honorable Frank Pallone Chairman Committee on Energy and Commerce United States House of Representatives Washington, D.C. 20515

The Honorable Cathy McMorris Rodgers Ranking Member Committee on Energy and Commerce United States House of Representatives Washington, D.C. 20515

Dear Chairman Pallone, Ranking Member McMorris Rodgers, Chairwoman Murray, and Ranking Member Burr;

The 89 undersigned organizations, representing patients with chronic and acute health conditions, write to urge that you take bold steps to improve the diversity of enrollment in clinical trials as part of this year's Prescription Drug User Fee Act (PDUFA) reauthorization.

Today, the majority of clinical trials fail overwhelmingly to achieve diverse enrollment - despite the fact that many serious and chronic diseases disproportionately impact underrepresented racial and ethnic minority groups. This lack of diversity in trial enrollment inhibits a full understanding of how safe and effective new drugs might be across their intended populations. It also exacerbates disparities in access to treatment when enrolling in a clinical trial may be a patient's most effective treatment option.

Improving clinical trial diversity is an imperative both for patient access and comprehensive scientific research. Despite racial and ethnic minority groups comprising nearly 40% of the US population, about 75% of participants in trials for drugs approved by the FDA in 2020 were white. When compared against the disproportionate burden of acute and chronic disease across racial and ethnic minority groups, this stark contrast highlights a growing problem contributing to both health and socioeconomic disparities. ²

Clinical trials should be available to all patients who qualify, including those who experience barriers to care and/or those who are from underrepresented communities. Reducing barriers to clinical trial participation is also good science. As America becomes more racially and ethnically diverse, a clinical trial system that fails to enroll patients from growing demographics will not support the pace of innovation that will help us meet our potential. We urge Congress to make real and meaningful reforms that will help ensure patients in every part of the country have access to the clinical trial care they need, while at the same time accelerating the development of new and better treatment options for patients for decades to come.

¹ US Food and Drug Administration, 2020 Drug Trials Snapshots: Summary Report, February 2021, https://www.fda.gov/media/145718/download

² Thorpe, KE. et al., *The United States can reduce socioeconomic disparities by focusing on chronic diseases*, August 17, 2017, Health Affairs Blog, https://www.healthaffairs.org/do/10.1377/hblog20170817.061561/full.

Promoting Sponsor Accountability for Enrollment Diversity

We are particularly pleased that the House Energy & Commerce Committee is taking up provisions related to promoting clinical trial diversity by increasing sponsor accountability. While the FDA encourages and supports sponsors developing diversity plans with enrollment targets, trial sponsors are not required to develop or submit these plans during the FDA's trial design review processes. Clinical trial sponsors should be required to build in specific, measurable enrollment targets as part of their trial design, prior to Phase II or III trials, to ensure that enrollment includes participants reflective of the diverse populations impacted by the specific disease or condition the therapy is intended to address. Incorporating diversity planning into the trial design process at its earliest stages would ensure that underrepresented groups aren't left behind and examine all aspects of trial design and conduct to diminish barriers.

Reduce Travel Burden for Trial Participants

In many cases, underrepresented groups may be less able to travel long distances to participate in a clinical trial, either from rural areas or even within urban areas. To promote trial access for these patients, trial designs must consider delivering certain clinical trial services outside of the centralized academic medical center setting. Trial flexibilities extended by the FDA during the COVID-19 public health emergency allowed certain trial services to be provided at community health facilities or in a patient's home, including the ability to utilize telemedicine and have interim toxicity evaluation visits, as long as precautions were in place to ensure reliable data. With two years of experience under these flexibilities, it is clear that some standardized services such as phlebotomy, traditional diagnostic imaging tests, and vitals checks can be provided safely and accurately by community providers in many cases. We urge Congress to make these flexibilities permanent in order to dramatically reduce travel and cost burdens on patients and reduce a key barrier to trial enrollment and retention.

We also look forward to working with you moving forward to address other barriers to increasing clinical trial participation and diversity and respectfully offer our support of the following policies for future consideration:

Improve Outreach to Underserved Patients & Providers

Investing in community-based providers is more likely to reach patients historically underrepresented in clinical trials. Community health centers are key to breaking down the barriers between the academic medical center and the healthcare teams patients already know and trust. However, many of these community providers are already stretched thin and lack the capacity to engage their patients in clinical trial enrollment. Federal resources should be directed towards community health center grant programs that support hiring and training culturally competent on-site personnel to conduct and recruit for trials, as well as implementing the IT systems necessary to seamlessly educate and enroll patients.

Minimize Financial Barriers

The cost associated with getting to a clinical trial location and making arrangements for family members can make enrolling in a clinical trial impossible. However, current federal fraud and abuse laws discourage sponsors from paying directly for digital technologies, transportation, lodging, and meals to trial participants and their families without the threat of legal action. This disincentive should be removed, and federal rules should clarify that sponsors can provide this assistance to trial enrollees without the threat of liability.

Conclusion

As America becomes more racially and ethnically diverse, a clinical trial system that fails to enroll patients from growing demographics will not support the pace of innovation that will help us meet our potential. We urge you to take real and meaningful steps towards this future.

Sincerely,

The Leukemia & Lymphoma Society
American Cancer Society Cancer Action

Network

Academy of Oncology Nurse & Patient

Navigators Accessia Health AliveAndKickn ALS Association

American Heart Association American Kidney Fund American Liver Foundation American Lung Association

American Society for Radiation Oncology Anxiety and Depression Association of

America

Association for Clinical and Translational

Science

Association for Clinical Oncology

Association of American Cancer Institutes Association of Community Cancer Centers

(ACCC)

Association of Oncology Social Work
Asthma and Allergy Foundation of America

Bladder Cancer Advocacy Network

Cancer ABCs

Cancer Support Community

Cancer Care

Case Western Reserve University School of

Medicine

Children's Cancer Cause Clinical Research Forum

College of American Pathologists Color of Crohn's & Chronic Illness

Colorectal Cancer Alliance
Dana-Farber Cancer Institute

Debbie's Dream Foundation: Curing

Stomach Cancer

Digestive Disease National Coalition

Duke Health

Epilepsy Foundation

Exon Group

Fight Colorectal Cancer

FORCE: Facing Our Risk of Cancer

Empowered

Friends of Cancer Research

GBS-CIDP Foundation International GLMA: Health Professionals Advancing

LGBTQ Equality
Global Liver Institute

GO2 Foundation for Lung Cancer Hemophilia Federation of America ICAN, International Cancer Advocacy

Network

International Myeloma Foundation

JDRF

Karen's Club KidneyCAN

Lazarex Cancer Foundation

Livestrong

LUNGevity Foundation

Lymphoma Research Foundation

Malecare Cancer Support Moffitt Cancer Center

National Brain Tumor Society

National Cancer Registrars Association National Comprehensive Cancer Network

National Eczema Association National Health Council

National Hemophilia Foundation National Kidney Foundation National LGBT Cancer Project

National Marrow Donor Program/Be The

Match

National MS Society

National Organization for Rare Disorders

National Pancreas Foundation

National Patient Advocate Foundation

National Psoriasis Foundation

National Scleroderma Foundation NephCure Kidney International Oncology Nursing Society Ovarian Cancer Research Alliance Pennsylvania Prostate Cancer Coalition

Pennsylvania

Prevent Cancer Foundation

Project Sleep

Prostate Health Education Network, Inc.

Perelman School of Medicine, University of

Seattle Indian Health Board Sleep Research Society St. Baldricks Foundation Susan G. Komen

The Consortium of MS Centers; The International Organization of MS Nurses

The Jed Foundation

The University of North Carolina at Chapel

Hill

Tigerlily Foundation

Triage Cancer

U.S. Against Alzheimer's

wAIHA Warriors

WomenHeart: The National Coalition for

Women with Heart Disease

ZERO - The End of Prostate Cancer